Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 1 Lymphoma, B-Cell 1

Interventions

Cyclophosphamide 25 Rituximab 22 fludarabine 14 Lenalidomide 10 Vincristine 8 Doxorubicin 8 Prednisone 7 Etoposide 7 fludarabine phosphate 6 Immunotherapy, Adoptive 5 polatuzumab vedotin 4 Cytarabine 4 CT-P10 4 Bendamustine Hydrochloride 4 Antigens, CD19 4 tocilizumab 3 Gemcitabine 3 Dexamethasone 3 Carboplatin 3 venetoclax 2 veltuzumab 2 prednylidene 2 ofatumumab 2 obinutuzumab 2 ixazomib 2 ibrutinib 2 etoposide phosphate 2 deltacortene 2 carmustine, poliferprosan 20 drug combination 2 acalabrutinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lymphoma, B-Cell × varlilumab × Clear all

NCT03307746 2024-12-02

RiVa

University Hospital Southampton NHS Foundation Trust

Phase 1/2 Completed

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡